Le Lézard
Classified in: Health, Science and technology
Subject: AWD

MGI Tech's DNBSEQ-T20x2* Gene Sequencer Named 2024 Edison Awardtm Gold Winner


FORT MYERS, Fla., April 19, 2024 /PRNewswire/ -- MGI Tech, a company committed to building core tools and technology to lead life science, is proud to announce that its DNBSEQ-T20x2* gene sequencer has been recognized with a Gold Edison Award in the "Health, Medical & Biotech" category.

"MGI is dedicated to unlocking the future of genomic technologies and pursuing excellence in building life science core tools," said Duncan Yu, President of MGI. "It is our pleasure and honor to be awarded the Edison Award for the first time. This recognition affirms our team's efforts in intelligent innovation as we continue to achieve outstanding results on the global stage."

Named after the prolific inventor Thomas A. Edison, the Edison Awards is one of the most prestigious technology accolades honoring excellence in new product development, design, and innovation. Thousands of innovations from around the world were reviewed by senior scientists, designers, engineers, marketers, and leading academics based on the four criteria of concept, value, delivery, and impact. The "Health, Medical & Biotech" category, in particular, honors products and services that have made a profound impact on patients and healthcare providers.

MGI's groundbreaking DNBSEQ-T20x2* ultra-high-throughput sequencer has been garnering significant attention since its debut in February 2023 for reducing genome sequencing costs to less than $100 per genome. This remarkable feat is not only facilitating the sequencing of a larger number of samples, but also empowering a more comprehensive, insightful, and precise analysis per sample.

The commercial success of DNBSEQ-T20x2* has enhanced overall sequencing capabilities and accelerated global scientific advances by doubling the efficiency of DNA sequencing. With its unparalleled throughput and exceptional cost-effectiveness, the sequencer is contributing to the development of the global genetic industry and driving progress in understanding the human genome and various medical applications.

Since its introduction, DNBSEQ-T20×2* has been received positively by leading global research institutions and healthcare providers, with corporate orders from the Shanghai-based JMDNA Biomedical Technology Co., Ltd, Prepaire Labs, a healthcare technology company in Abu Dhabi, and Eurofins Genomics, one of the key emerging players in specialty esoteric and molecular clinical diagnostic testing in Europe and the United States.

In addition to the Edison Award, DNBSEQ-T20×2* has also garnered numerous recognitions, including the 2023 R&D 100 Awards, BEYOND Healthcare Innovation Award, 2023 BioTech Breakthrough Awards, and 2023 Globee® Awards, for its cutting-edge innovation and positive impact on global health.

For more information about the DNBSEQ-T20x2* gene sequencer, visit https://en.mgi-tech.com/products/instruments_info/33/.

###

About MGI

MGI Tech Co. Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers*, and its multi-omics platforms include genetic sequencing*, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on TwitterLinkedIn or YouTube.

*For now, this product is provided for Research Use Only and not for use in diagnostic procedures.

About Edison Awardstm

Established in 1987, the Edison Awards are dedicated to recognizing, honoring and fostering innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, design and innovation. Past award recipients include Steve Jobs, Elon Musk, and leaders of global corporations such as Coca-Cola, Genentech, General Electric, General Motors, IBM and Campbell Soup Co. In 2021, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit www.edisonawards.com.

SOURCE MGI


These press releases may also interest you

at 13:11
Jones Walker LLP is pleased to welcome Greg Schafer and Valerie Fontenot as special counsel in the firm's Litigation Practice Group and members of the firm's growing Healthcare Industry Team in the New Orleans office....

at 13:05
Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced that Lucas Harrington, Ph.D., Mammoth's co-founder and Chief...

at 13:00
Patients with liver cancer in the southeast can stay closer to home and trust they'll receive the latest, most advanced care as Northeast Georgia Medical Center (NGMC) recently completed the first histotripsy procedure in the state of Georgia....

at 12:56
Johnson & Johnson has proposed a $6.48 billion settlement in the talc-ovarian cancer litigation, hoping to reach consensus for the deal with the tens of thousands of women and families who have filed claims. If 75% of the claimants agree to the...

at 12:44
Allucent, a global mid-sized clinical research organization (CRO), received two CRO Leadership Awards presented by Clinical Leader and Life Science Connect for the second consecutive year. Recipients of these awards are determined based on research...

at 12:40
The "Nanobiotechnology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Nanobiotechnology Market to Reach $160.3 Billion by 2030 The global market for Nanobiotechnology estimated at US$100...



News published on and distributed by: